Evolus Announces EMA Acceptance For Review Of The Marketing Authorization Application For DWP-450 Neuromodulator

Published: Jul 20, 2017

SANTA BARBARA, Calif., July 20, 2017 /PRNewswire/ -- Evolus Inc. (www.Evolus.com) received confirmation from the European Medicines Agency (EMA) that the Marketing Authorization Application (MAA) for DWP-450, a Botulinum toxin Type A, for the treatment of adult patients with glabellar lines, also known as "frown lines" between the eyebrows, has been accepted for review.

 (PRNewsfoto/Evolus Inc.)

The MAA application is supported by the results of a Phase III randomized, multi-center, placebo-controlled, double blind trial (EVB-003). Over 500 adult male and female subjects participated in the clinical trial, which is being reviewed under the Centralized Procedure.  The Centralized Procedure allows applicants to obtain a marketing authorization that is valid throughout the European Union. 

Murthy Simhambhatla, CEO of Evolus, said, "The MAA acceptance for review under the Centralized Procedure is a significant milestone achievement for the DWP-450 development program. We look forward to working with the EMA during the agency's review of the application."

About Evolus Inc.

Evolus Inc. is a privately held company focused on bringing highly innovative products and services to the aesthetics market. Evolus' lead product candidate is DWP-450, a Botulinum toxin Type A for the treatment of glabellar lines.

Evolus Press Contacts:
September Riharb, Vice President, Marketing  
Tel: +1-805-764-6300
Email: September.Riharb@Evolus.com

Jeff Plumer, Vice President, Legal
Tel: +1-949-284-4555
Email: Jeff.Plumer@Evolus.com

View original content with multimedia:http://www.prnewswire.com/news-releases/evolus-announces-european-medicines-agency-acceptance-for-review-of-the-marketing-authorization-application-for-dwp-450-neuromodulator-300491558.html

SOURCE Evolus Inc.

Back to news